Zacks Investment Research lowered shares of Capricor Therapeutics (NASDAQ:CAPR) from a hold rating to a sell rating in a research report report published on Tuesday morning.
According to Zacks, “Capricor Therapeutics, Inc. is a biotechnology company. It is focused on the development of novel therapeutics to prevent and treat heart disease. The Company has two drug candidates in development: Cenderitide and CU-NP. Capricor Therapeutics, Inc., formerly known as Nile Therapeutics, Inc., is based in San Mateo, California. “
CAPR has been the subject of several other research reports. ValuEngine upgraded shares of Capricor Therapeutics from a sell rating to a hold rating in a report on Wednesday, January 2nd. TheStreet cut shares of Capricor Therapeutics from a c- rating to a d+ rating in a report on Monday, October 15th. HC Wainwright decreased their price target on shares of Capricor Therapeutics from $8.60 to $3.50 and set a buy rating for the company in a research note on Monday, December 31st. Finally, Maxim Group reiterated a buy rating and set a $4.00 price target on shares of Capricor Therapeutics in a research note on Wednesday, November 14th. One analyst has rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The stock has a consensus rating of Hold and a consensus target price of $3.00.
Capricor Therapeutics (NASDAQ:CAPR) last issued its earnings results on Tuesday, November 13th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.01). Capricor Therapeutics had a net margin of 24.75% and a negative return on equity of 159.36%. The company had revenue of $0.22 million during the quarter, compared to analyst estimates of $0.90 million. Analysts expect that Capricor Therapeutics will post -0.57 earnings per share for the current year.
About Capricor Therapeutics
Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.
Recommended Story: Using the New Google Finance Tool
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.